Description

The Seizure Severity Questionnaire (SSQ-11) is a standardized patient-reported outcome measure specifically developed to assess the severity, burden, and overall impact of epileptic seizures from the patient’s perspective. Introduced by Cramer and French (2001), the questionnaire was designed to complement traditional clinical indicators, such as seizure frequency, by capturing the subjective experiences associated with epileptic events and their effects on daily functioning and quality of life.

Unlike conventional clinical assessments that primarily focus on the number of seizures, the SSQ-11 evaluates the multidimensional nature of seizure severity by examining symptoms and experiences occurring before (preictal), during (ictal), and after (postictal) a seizure. The instrument explores a wide range of seizure-related characteristics, including warning signs, physical and cognitive symptoms, emotional responses, recovery time, functional impairment, and the overall disruptive impact of seizures on everyday activities.

The SSQ-11 is widely used in neurology, epileptology, clinical trials, rehabilitation medicine, and health outcomes research. It provides clinicians and researchers with valuable information regarding patients’ subjective experiences, enabling a more comprehensive evaluation of treatment effectiveness beyond seizure frequency alone. The questionnaire is particularly useful for monitoring disease progression, evaluating therapeutic interventions, assessing antiepileptic drug efficacy, and measuring health-related quality of life in individuals living with epilepsy.

Data Analysis and Use

The analysis of data obtained from the Seizure Severity Questionnaire (SSQ-11) involves comprehensive psychometric and statistical evaluation to quantify the severity and functional impact of epileptic seizures. Individual responses are transformed into numerical scores that reflect the patient’s experiences before, during, and after seizure episodes, allowing healthcare professionals to evaluate both the intensity of symptoms and their influence on daily life.

Psychometric evaluation includes the assessment of internal consistency, commonly measured using Cronbach’s alpha coefficient, to determine the reliability of the questionnaire. Test–retest reliability is examined to assess the stability of patient responses over repeated administrations when seizure characteristics remain unchanged. The construct validity of the instrument is evaluated through correlations with established epilepsy outcome measures, seizure frequency indices, health-related quality of life questionnaires, and clinical assessments, confirming that the SSQ-11 accurately measures seizure severity from the patient’s perspective.

Statistical analyses frequently include descriptive statistics, correlation analyses, regression models, responsiveness analyses, and longitudinal comparisons to evaluate treatment effects, monitor disease progression, and investigate associations between seizure severity and variables such as medication adherence, psychological distress, cognitive functioning, social participation, and overall quality of life.

The SSQ-11 is extensively applied in clinical practice to monitor patient outcomes and guide treatment decisions, while in research settings it serves as an important outcome measure in clinical trials evaluating new antiepileptic therapies and interventions aimed at reducing seizure burden and improving patient-centered outcomes.

Objective

The primary objective of the Seizure Severity Questionnaire (SSQ-11) is to provide a reliable, valid, and clinically meaningful assessment of the subjective severity and overall burden of epileptic seizures. The questionnaire enables clinicians and researchers to evaluate aspects of seizure experience that cannot be adequately captured by seizure frequency alone, including symptom intensity, functional impairment, emotional distress, and postictal recovery.

By providing standardized patient-reported measurements, the SSQ-11 facilitates comprehensive assessment of therapeutic effectiveness, allowing healthcare professionals to determine whether treatments reduce not only the number of seizures but also their severity and impact on patients’ everyday lives. The instrument also supports individualized clinical management, long-term monitoring of disease progression, and evidence-based decision-making regarding pharmacological and non-pharmacological interventions.

Furthermore, the SSQ-11 contributes to research examining the relationship between seizure severity, treatment response, psychosocial functioning, and health-related quality of life, making it an essential tool in modern epilepsy research and clinical care.

Scoring

The Seizure Severity Questionnaire (SSQ-11) consists of 11 primary questions and 22 supplementary sub-items that evaluate patients’ experiences during the preictal, ictal, and postictal phases of epileptic seizures.

Participants are asked to rate the extent to which they experienced specific symptoms or difficulties using a 7-point Likert-type scale, typically ranging from 1 (Not at all bothered) to 7 (Extremely or constantly bothered). Responses reflect the intensity, frequency, and disruptive nature of seizure-related experiences.

Individual item scores are combined to generate a total severity score, with possible values ranging from 1 to 175. Higher total scores indicate greater seizure severity, increased symptom burden, more pronounced functional impairment, and a stronger negative impact on quality of life.

In addition to total score calculation, researchers frequently evaluate descriptive statistics, score distributions, responsiveness to treatment, floor and ceiling effects, and psychometric indicators such as Cronbach’s alpha, item-total correlations, and construct validity to confirm the reliability and clinical applicability of the questionnaire across different patient populations.

Psychometric Properties

The SSQ-11 has demonstrated satisfactory psychometric performance across clinical validation studies. The instrument exhibits acceptable internal consistency, with a reported Cronbach’s alpha coefficient of approximately 0.76, indicating good coherence among questionnaire items.

Its test–retest reliability, reported at approximately 0.74, demonstrates that the questionnaire provides stable and reproducible measurements over time when seizure characteristics remain unchanged. Furthermore, studies evaluating construct validity have reported statistically significant correlations between SSQ-11 scores and other established epilepsy outcome measures, supporting the instrument’s ability to accurately assess seizure severity and its clinical consequences.

These psychometric characteristics establish the SSQ-11 as a reliable and valid patient-reported outcome measure suitable for routine clinical practice, observational studies, and randomized clinical trials evaluating epilepsy treatments.

References

Cramer, J. A., & French, J. A. (2001). Development and Validation of a Seizure Severity Questionnaire for Clinical Trials in Epilepsy. Epilepsia.

Baker, G. A., Smith, D. F., Dewey, M., Jacoby, A., & Chadwick, D. W. (1997). The Initial Development of a Health-Related Quality of Life Model as an Outcome Measure in Epilepsy. Epilepsy Research, 28(1), 65–81.

Devinsky, O., Vickrey, B. G., Cramer, J., Perrine, K., Hermann, B., Meador, K., & Hays, R. D. (1995). Development of the Quality of Life in Epilepsy Inventory (QOLIE-31). Epilepsia, 36(11), 1089–1104.

Wiebe, S., Eliasziw, M., & Matijevic, S. (2001). Changes in Quality of Life in Epilepsy: How Large Must They Be to Be Real? Epilepsia, 42(1), 113–118.